: iStockAnalyst.com Symbols Feed

EXACT Sciences (NASDAQ:EXAS): Back On Track, Report Available

Wed, 15 Jul 2009 13:13:00 GMT

EXACT Sciences (NASDAQ:EXAS) provides a timely case study on the current debate over healthcare reform in the U.S. Our current "sick-care" system focuses on the treatment of disease rather than preventative medicine initiatives through investments in wellness programs and improved diagnostic screening tests - particularly in the area of cancer screening since this represents a fast-growing, costly disease. The Company's next-generation screening test (V3) for colorectal cancer (CRC) (...)[More...]

Bret Barakett's Tremblant Capital Group Bets On Technology: 13F Filing Q1 2009

Wed, 10 Jun 2009 16:15:00 GMT

This is the 1st Quarter 2009 edition of our ongoing hedge fund portfolio tracking series. Before reading this update, make sure you check out the Hedge Fund 13F filings series preface. Next up, we have Tremblant Capital Group. Tremblant is a $3 billion hedge fund based in New York and is run by Bret Barakett, who is a former portfolio manager at Moore Capital Management (the hedge fund run by the great Louis Bacon, whom we also track). If the last name of 'Barakett' sounds familiar, its because his brother, Timothy Barakett, manages fellow hedge fund Atticus Capital, whose portfolio we recently covered. Taken from their site, Tremblant Capital Group's objective is "to achieve superior risk adjust returns[More...]

Sequenom (NasdaqGM: SQNM) Splattered, EXACT Sciences (NasdaqCM: EXAS) On The Rise

Wed, 06 May 2009 12:11:06 GMT

With Sequenom (SQNM) losing about three-quarters of its market value in pre-market trading to around 3 bucks per share; EXACT Sciences (EXAS) is poised to continue its comeback from penny stock levels late last year and has a chance to close the year at a[More...]

Sequenom (NASDAQ:SQNM) Splattered, EXACT Sciences (NASDAQ:EXAS) On The Rise

Thu, 30 Apr 2009 16:33:17 GMT

With Sequenom (NASDAQ:SQNM) losing about three-quarters of its market value in pre-market trading to around 3 bucks per share; EXACT Sciences (NASDAQ:EXAS) is poised to continue its comeback from penny stock levels late last year and has a chance to close the year at a higher market value than its molecular diagnostics rival. SQNM launched a hostile, all-stock tender offer for EXAS earlier this year for $1.50 per share (which would now be valued at less than 40 cents), but EXACT reject (...)[More...]

Earnings Review: February 02, 2009

Tue, 03 Feb 2009 00:19:04 GMT

Late on Monday, Aflac Inc. (NYSE: AFL) announced that fourth-quarter net income plunged 48% to $197 million, or 42 cents a share, from $382 million, or 78 cents a share in the same quarter, a year ago.[More...]

Earnings Review: 11th November

Wed, 12 Nov 2008 03:11:00 GMT

Late on Tuesday, Redmond, Washington based Concur Technologies Inc. (NASDAQ: CNQR) announced that its fourth-quarter net earnings jumped more than 36% $5.6 million, or 11 cents per share.[More...]

Earnings After Market Close (11/11/2008)

Tue, 11 Nov 2008 18:17:00 GMT

Stock Symbols: GIVN,EVOL,SPC,BRKS,SMTL,BOBE,BPHX,NTY,ATO,COMV,CXO,HOLX,HOO,WES,APU,EGMI,ERII,CNQR,HMIN,IMOS,PXG,QBAK,PBR[More...]

After Gustav & Labor Day

Tue, 02 Sep 2008 14:26:00 GMT

Good morning. We're set for a positive start to September as oil prices fall significantly after Gustav failed to wreak havoc to critical energy facilities over the holiday weekend. In other news, Korea Development Bank confirmed that it is in talks to invest in Lehman Brothers. On Friday,[More...]

Analyst Comments: Enzon Pharma, BHP Billiton, Lincoln Electric, Hologic, Ardea Biosciences, Gafisa, Buckeye Partners, Take-Two

Mon, 18 Aug 2008 18:50:00 GMT

Enzon Pharmaceuticals? (ENZN) key product Abelcet, a treatment for fungal infections, sales continued to deteriorate in 2008. Further, another major source of revenue, Royalty, is also under pressure from competition. However, sales in two other products, Oncaspar (for acute lymphoblastic leukemia) and Adagen (for severe combined immunodeficiency disease) are picking up momentum and offsetting the sales decline from Abelcet and Royalty. We are impressed with strong sales growth of Oncaspar. We expect total revenue to remain stable or experience modest growth in the coming years while the company is progressing well with its clinical developments. Enzon is also advancing its pipeline to drive long-term growth. We maintain our Hold rating on the shares. We see a balanced risk/reward profile for Enzon. In our view, there are limited near-term catalysts to[More...]

Weak Economic Data

Thu, 31 Jul 2008 14:47:00 GMT

Good morning. A plethora of disappointing economic data (GDP, jobless claims, Monster Employment Index) have offset a number of better than expected earnings reports this morning. Premarket futures are pointing to a weak start to the last trading day of July. Premarket gainers: CADX, IMCL, MOT, PDGI, [More...]

Biotech Company Raises Venture Capital, Will Move to Madison

Thu, 13 Aug 2009 07:51:00 GMT

Aug. 13--Flex Biomedical Inc., a privately held company developing treatments for orthopedic diseases, said it has raised $985,000 in Wisconsin, including a $150,000 loan from the state's Technology Venture Fund, and will move its operations to Madison from Boston.
Three of the state's early-stage investment groups -- Wisconsin Investment Partners in Madison, NEW Capital Fund in Appleton and Marquette University Golden Angels Network in Milwaukee -- have invested in the company.
Flex Biomedical, which employs three people, plans to begin clinical trials late next year or in early 2011 on a synthetic polymer to treat osteoarthritis, said Sal Braico, the company's chief executive, who has moved to Madison.

: iStockAnalyst.com Symbols Feed

EXACT Sciences (NASDAQ:EXAS): Back On Track, Report Available

Bret Barakett's Tremblant Capital Group Bets On Technology: 13F Filing Q1 2009

Sequenom (NasdaqGM: SQNM) Splattered, EXACT Sciences (NasdaqCM: EXAS) On The Rise

Sequenom (NASDAQ:SQNM) Splattered, EXACT Sciences (NASDAQ:EXAS) On The Rise

Earnings Review: February 02, 2009

Earnings Review: 11th November

Earnings After Market Close (11/11/2008)

After Gustav & Labor Day

Analyst Comments: Enzon Pharma, BHP Billiton, Lincoln Electric, Hologic, Ardea Biosciences, Gafisa, Buckeye Partners, Take-Two

Weak Economic Data

Biotech Company Raises Venture Capital, Will Move to Madison

Hologic receives FDA approval for two Cervista HPV tests

THE OUTLOOK ; February 2009

Horrible Stock Year Ends

Study Links Fetal Fibronectin Testing with Changes in Management Decisions for Symptomatic and Asymptomatic Women at Risk for Preterm Birth

Hologic Announces Third Quarter Fiscal 2009 Operating Results

Photos: One Million Patients Choose Hologic's NovaSure(R) System Over Hysterectomy

Hologic to Present at the 29th Annual Canaccord Adams Global Growth Conference

Hologic to Release Third Quarter Fiscal 2009 Operating Results on Monday, August 3, 2009

Video: FDA Approves Hologic's Adiana(R) Permanent Contraception System

Photos: FDA Clears Hologic R2(TM) DigitalNow(TM) HD Software Application

Battle Road Research Expands Healthcare Coverage and Launches Blog

Hologic to Present at Two Investor Healthcare Conferences

MaybachFinancial.Com Posts Free Analyst Report on HNZ, CCJ, DBD and HOLX

Form 4 HOLOGIC INC For: Oct 30 Filed by: MUIR GLENN P (10K)

Form 4 HOLOGIC INC For: Oct 30 Filed by: CASCELLA ROBERT (10K)

Form 4 HOLOGIC INC For: Oct 30 Filed by: CUMMING JOHN W (10K)

Form 4 HOLOGIC INC For: Sep 21 Filed by: MUIR GLENN P (10K)

Form 4 HOLOGIC INC For: Aug 31 Filed by: STEIN JAY A (10K)

Form 4 HOLOGIC INC For: Aug 26 Filed by: LAVALLEE ROBERT H (10K)

Form 4 Brady David J For: Aug 20 (10K)

Form 4 HOLOGIC INC For: Aug 19 Filed by: CUMMING JOHN W (10K)

Form 4 HOLOGIC INC For: Aug 14 Filed by: CASCELLA ROBERT (10K)

Form 4 Brady David J For: Aug 06 (10K)